This study is investigating whether adding Allogeneic Bone Marrow Derived Multipotent Mesenchymal Stromal Cells (MSCs) can help people with treatment-resistant bipolar depression. MSCs are special cells taken from bone marrow. You would receive either the MSCs or a placebo (an inactive substance) in addition to your usual care. Researchers want to see if MSCs can improve depression symptoms, measured by a scale called the Montgomery-Åsberg Depression Rating Scale (MADRS). The study is looking for 30 participants between 18 and 65 years old who have been diagnosed with Bipolar I or II disorder and have significant depressive symptoms. The current status of this study is unclear.

Study design

This is a randomized, double-blind, placebo-controlled study, meaning participants are randomly assigned to receive either the active treatment or a placebo, and neither you nor your doctors will know which you are receiving. It plans to enroll 30 participants.

What's involved

You would receive a single infusion of MSCs or placebo up to one week after joining the study. The main treatment period lasts eight weeks, and you will also have assessments at week 26.

Compensation

Not stated in the trial record.

Follow-up

Participants will be assessed at week 8 and again at week 26 after the initial treatment.

AI-generated from the public study record. Only the study team can confirm whether you're eligible — confirm details with them before making decisions.